{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:30:10Z","timestamp":1778301010473,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-023-00784-8","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T21:04:12Z","timestamp":1674075852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Model-Informed Approach Supporting Approval of Nexviazyme (Avalglucosidase Alfa-ngpt) in Pediatric Patients with Late-Onset Pompe Disease"],"prefix":"10.1208","volume":"25","author":[{"given":"Ruo-Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Drozda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann R.","family":"Punnoose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda J. B.","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet W.","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pacanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"784_CR1","doi-asserted-by":"publisher","first-page":"15856","DOI":"10.18632\/aging.103794","volume":"12","author":"S Taverna","year":"2020","unstructured":"Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, Zora M, Scalia S, Brando C, Curto AL, Marsana EM, Olivieri R, Vitale S, Duro G. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging (Albany NY). 2020;12:15856\u201374.","journal-title":"Aging (Albany NY)"},{"key":"784_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.21037\/atm.2019.04.70","volume":"7","author":"A Hahn","year":"2019","unstructured":"Hahn A, Schanzer A. Long-term outcome and unmet needs in infantile-onset Pompe disease. Ann Transl Med. 2019;7:283.","journal-title":"Ann Transl Med"},{"key":"784_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13023-020-01353-4","volume":"15","author":"P Vanherpe","year":"2020","unstructured":"Vanherpe P, Fieuws S, D\u2019Hondt A, Bleyenheuft C, Demaerel P, De Bleecker J, Van den Bergh P, Baets J, Remiche G, Verhoeven K, Delstanche S, Toussaint M, Buyse B, Van Damme P, Depuydt CE, Claeys KG. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures. Orphanet J Rare Dis. 2020;15:83.","journal-title":"Orphanet J Rare Dis"},{"key":"784_CR4","unstructured":"U.S. Food and Drug Administration (FDA). Integrated review for NEXVIAZYME\u2122 (Avalglucosidase alfa-ngpt). 2021.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761194Orig1s000IntegratedR.pdf.\u00a0Accessed 22 Sep 2022."},{"key":"784_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.21037\/atm.2019.04.15","volume":"7","author":"HV Do","year":"2019","unstructured":"Do HV, Khanna R, Gotschall R. Challenges in treating Pompe disease: an industry perspective. Ann Transl Med. 2019;7:291.","journal-title":"Ann Transl Med"},{"key":"784_CR6","doi-asserted-by":"publisher","unstructured":"Punnoose AR, Jeng LJB, Maynard JW, Review Team. Regulatory news: Avalglucosidase alfa-ngpt (Nexviazyme) for late-onset Pompe disease-FDA approval summary. J Inherit Metab Dis. 2022;45:1015\u201317. https:\/\/doi.org\/10.1002\/jimd.12543","DOI":"10.1002\/jimd.12543"},{"key":"784_CR7","unstructured":"U.S. Food and Drug Administration (FDA). Drug labeling for NEXVIAZYME\u2122 (avalglucosidase alfa-ngpt). 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761194s000lbl.pdf.\u00a0Accessed 22 Sep 2022."},{"key":"784_CR8","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cpt.1363","volume":"105","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhu H, Madabushi R, Liu Q, Huang SM, Zineh I. Model-informed drug development: current US regulatory practice and future considerations. Clin Pharmacol Ther. 2019;105:899\u2013911.","journal-title":"Clin Pharmacol Ther"},{"key":"784_CR9","unstructured":"U.S. Food and Drug Administration (FDA). Model-informed drug development pilot program. https:\/\/www.fda.gov\/drugs\/development-resources\/model-informed-drug-development-pilot-program. Accessed 16 Aug 2022."},{"key":"784_CR10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","volume":"22","author":"AA Khan","year":"2020","unstructured":"Khan AA, Case LE, Herbert M, DeArmey S, Jones H, Crisp K, Zimmerman K, ElMallah MK, Young SP, Kishnani PS. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature. Genet Med. 2020;22:898\u2013907.","journal-title":"Genet Med"},{"key":"784_CR11","doi-asserted-by":"crossref","unstructured":"Ditters IAM, Huidekoper HH, Kruijshaar ME, Rizopoulos D, Hahn A, Mongini TE, Labarthe F, Tardieu M, Chabrol B, Brassier A, Parini R, Parenti G, van der Beek N, van der Ploeg AT, van den Hout JMP, d. European Pompe Consortium project group on classic infantile Pompe. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium. Lancet Child Adolesc Health. 2022;6:28\u201337.","DOI":"10.1016\/j.ymgme.2021.11.087"},{"key":"784_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/jimd.12268","volume":"43","author":"E Poelman","year":"2020","unstructured":"Poelman E, van den Dorpel JJA, Hoogeveen-Westerveld M, van den Hout JMP, van der Giessen LJ, van der Beek N, Pijnappel W, van der Ploeg AT. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients. J Inherit Metab Dis. 2020;43:1243\u201353.","journal-title":"J Inherit Metab Dis"},{"key":"784_CR13","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1515\/jpem-2018-0336","volume":"31","author":"M Spada","year":"2018","unstructured":"Spada M, Pagliardini V, Ricci F, Biamino E, Mongini T, Porta F. Early higher dosage of alglucosidase alpha in classic Pompe disease. J Pediatr Endocrinol Metab. 2018;31:1343\u20137.","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-023-00784-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-023-00784-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-023-00784-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:07:42Z","timestamp":1677082062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-023-00784-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["784"],"URL":"https:\/\/doi.org\/10.1208\/s12248-023-00784-8","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"22 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All listed authors are employees of the Food and Drug Administration of the United States. The authors report no financial interests or relationships with the commercial sponsors of any products discussed in this report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The views expressed in this article are those of the authors and do not necessarily reflect the official views of the FDA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"16"}}